|
Pipeline Insight: Hematological Malignancies – Pursuit for the next blockbuster intensifies
Unmet needs across the hematological malignancies remain high, with most traditional therapies conferring low levels of specificity and high toxicity. Pipeline candidates classified as molecular targeted therapies, cytotoxic therapies and immunotherapeutic agents, may offer attractive therapeutic additions and Datamonitor’s insight into their clinical and commercial potential is provided.
The gold-standard and blockbuster status achieved by Novartis’ Gleevec (imatinib) in chronic myeloid leukemia (CML) and Biogen Idec/Genentech/Roche’s Rituxan (rituximab) in non- Hodgkin’s lymphoma (NHL) has helped to catalyze pipeline activity, reflected by the finding that there are 180 different products in clinical development for hematological malignancies, 143 (79per cent) of which are either targeted or immunotherapeutic agents. This segmentation reflects the shift towards designing agents directed against specific molecular abnormalities unique to malignant cells.
View
Table Of Contents >
|
